LANDMARK DEAL FOR UQ-TRINITY INFLAMMATION START-UP
A start-up company developing treatments for inflammatory diseases based on a research partnership between The University of Queensland and Trinity College Dublin (TCD) has been acquired in a landmark deal – one of the largest in Australian and Irish biotech history.
Inflazome has been acquired by Roche for an upfront cash payment of €380 million (about $A617 million), plus additional payments based on the achievement of certain milestones.
The IP behind Inflazome’s drug candidates is based on a research partnership between Professor Matt Cooper, Professor Kate Schroder, Dr Rebecca Coll and Professor Avril Robertson from UQ’s Institute for Molecular Bioscience and Professor Luke O’Neill from Trinity College Dublin.
-
- Category: News
- Date: September 22, 2020
- Added By: ImagingCoE
-
-